MazdutideDual GLP-1/glucagon receptor agonist
Mazdutide combines GLP-1 and glucagon receptor activity. Its studies examine weight and metabolic outcomes, with much of the clinical programme conducted in China.
What is Mazdutide?
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for weight and metabolic outcomes, including in Chinese clinical populations.
How it works
It combines GLP-1-related appetite signalling with glucagon-receptor activity. This differs from the GIP/GLP-1 combination used by tirzepatide.
Effects studied
What does the evidence show?
Randomised metabolic studies; archived primary references retained
Two pathways with different jobs
GLP-1 signalling helps regulate appetite and glucose-dependent insulin secretion. Glucagon affects liver metabolism and energy handling. Mazdutide combines activity at both receptors, aiming to produce a useful overall metabolic effect rather than simply increasing or decreasing one hormone in isolation.
Not the same as every dual agonist
The phrase “dual agonist” can conceal important differences. Tirzepatide targets GLP-1 and GIP; mazdutide targets GLP-1 and glucagon. Shared terminology does not make their mechanisms, trial results or suitability interchangeable. Direct comparisons are more informative than comparisons between separate headlines.
Where the evidence comes from
The retained research includes randomised studies in Chinese participants examining body weight and related metabolic outcomes. Their interpretation depends on who took part, how long treatment lasted and how the results were analysed. Even substantial weight loss in one setting does not reliably predict the result in every European patient group.
What belongs beside the benefit
Average weight change needs to be considered alongside gastrointestinal tolerability, treatment discontinuation, glucose control and longer-term outcomes. Less liver fat also does not by itself show that liver complications become less frequent. Authorisation or availability elsewhere does not establish the same status in Germany or Switzerland.
Safety & status
Gastrointestinal tolerability, glucose-related effects and continued participation in treatment are relevant to its clinical evaluation.
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Is mazdutide the same receptor combination as tirzepatide?
No. Mazdutide combines GLP-1 and glucagon activity; tirzepatide combines GLP-1 and GIP activity.
Does less liver fat prove protection from liver complications?
No. Imaging, liver inflammation, fibrosis and clinical complications are distinct outcomes.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Mazdutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Mazdutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Mazdutide · retained primary-paper lead Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.